Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R



TSX:CXR.R - Post by User

Comment by cashflow98on Jan 15, 2016 1:44pm
198 Views
Post# 24462814

RE:News Concordia Thompson present on Jan 20 at cibc conference

RE:News Concordia Thompson present on Jan 20 at cibc conference
Princeps979 wrote: News Concordia Thompson present on Jan 20 at cibc conference


Concordia Healthcare to Present at CIBC Investor Conference OAKVILLE, ON, Jan. 15, 2016 - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, announced today that its Chairman and CEO Mark Thompson is scheduled to deliver a corporate presentation at the CIBC 19th Annual Whistler Institutional Investor Conference on January 20th, 2016 at 4:00 p.m. PT in Whistler, B.C. Interested parties can listen to a live audiocast of the presentation by clicking the following link: https://webcasts.welcome2theshow.com/cibcwhistler2016/concordia The presentation will also be available by audio replay by clicking the link above. About Concordia Concordia is a diverse, international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs. The Company has an international footprint with sales in more than 100 countries, and has a diversified portfolio of more than 200 established off-patent molecules. Concordia also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia operates out of facilities in Oakville, Ontario and, through its subsidiaries, operates out of facilities in Bridgetown, Barbados; Roanoke, Virginia; London, England; Mumbai, India; and Chicago, Illinois. SOURCE Concordia Healthcare Corp. For further information: Adam Peeler, Concordia Healthcare Corp., 905-842-5150 x 250, apeeler@concordiarx.com
<< Previous
Bullboard Posts
Next >>